Earlier this week, it was a pleasure to celebrate the 20th anniversary of the National Collaborative Research Infrastructure Strategy (NCRIS) at Parliament House, where leaders from government, research and industry came together to mark two decades of NCRIS and its impact on Australia’s research landscape.
For 20 years, NCRIS has formed the backbone of Australia’s research capability. Through nationally coordinated investment and collaboration across institutions, NCRIS has built one of the world’s most respected research infrastructure systems – delivering impact across health, agriculture, energy, defence, environmental science and advanced manufacturing.
Several messages stood out throughout the evening. Assistant Minister Julian Hill described NCRIS as “the backbone of Australia’s national research” and a critical enabler of the country’s research capability. He noted that the program’s longevity reflects its genuine value and the bipartisan support it has earned over the past two decades.
The Hon Kim Carr described NCRIS as “one of the most effective nation-building investments” and “a proven model of collaboration.” He also reminded the audience that NCRIS is an investment not only in research, but in Australia’s productivity, resilience and future prosperity.
One message resonated: world-class research doesn’t happen by chance. It relies on sustained investment in infrastructure, collaboration and the expertise of the people who make it all possible.
As a founding member of NCRIS, Phenomics Australia has been embedded in this journey from the beginning. Our infrastructure, expertise, and collaborations are a critical part of the broader NCRIS ecosystem that enables cutting-edge research and innovation not only across Australia but globally.
Phenomics Australia enables the discovery of disease mechanisms, translation into clinical and commercial outcomes, and collaboration across research, healthcare and industry.
During the event at Parliament House, we were proud to showcase one of Phenomics Australia’s standout success stories, the Rastrum bioprinter by Inventia Life Science.
Using live cells, the Rastrum bioprinter can print models of tumours, skin, brain, liver and breast tissue and many others, helping to advance biomedical research and drug discovery. Today, this Australian innovation is sold in 26 countries.
To learn more about this Phenomics Australia impact case, visit: ➡️ https://phenomicsaustralia.org.au/industry-partnerships-for-health-technology-innovation-the-inventia-rastrum-3d-bioprinter/
